WO2010119133A1 - Methods and tools for predicting the efficiency of anthracyclines in cancer - Google Patents
Methods and tools for predicting the efficiency of anthracyclines in cancer Download PDFInfo
- Publication number
- WO2010119133A1 WO2010119133A1 PCT/EP2010/055067 EP2010055067W WO2010119133A1 WO 2010119133 A1 WO2010119133 A1 WO 2010119133A1 EP 2010055067 W EP2010055067 W EP 2010055067W WO 2010119133 A1 WO2010119133 A1 WO 2010119133A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- genes
- gene set
- top2a
- index
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention is related to methods and tools (gene set and kit or device) to predict the efficiency of an anthracycline (s) -based regimen in mammal subjects affected by an hyperpr o 1 i f er a t i ve disorder (cancer) , especially human patients affected by this disorder, especially human patients affected by Breast cancer (BC) .
- BC Breast cancer
- Breast cancer is an heterogeneous disease that can be subdivided into subgroups depending on markers .
- oestrogen receptor (ER) positive status is associated with a better outcome and may predict for a response to hormone treatments.
- Her2 (ERBB2, neu) o v e r e xp r e s s i o n is associated to a worse outcome, but Her2-specific treatments, such as administration of monoclonal antibodies (trastuzumab or herceptin) , may be beneficial for those patients .
- Anthracyclines-based regimens are among the most active chemotherapies in Breast Cancer. However, their clinical use is associated with rare but severe toxicities, such as long-term hematological disorders (myelodisplastic syndrome and leukemia) and cardiac heart failure. Also the efficacy of anthracyclines appears to be restricted to a subset of the Breast Cancer patient population. Therefore, the identification of molecular markers that could predict a response of breast tumors to anthracyclines-based chemotherapy remains a priority.
- TOP2A Topoisomerase II alpha
- FISH results appear to be linked to a high variability between different test centres and up to 31% of discordance between local and central labs has been reported for FISH measurement of Her2 and/or TOP2A (Di Leo A et al, Cancer Res., 69 suppl (abstr 705) 2009) .
- the present invention aims to provide new detection methods and tools that do not present the drawbacks of the state of the art.
- the present invention aims to provide such methods and tools that improve the prediction of a response to antracyclines (-based) regimens in breast cancer patients .
- the present invention relates to a gene set representing TOP2A index.
- the TOP2A index is measured by a mRNA quantification of these selected genes.
- the genes corresponding to the gene set representing the Top2A index are isolated.
- the gene set of the invention comprises (or consist of) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or all the genes mentioned in Table 1.
- the present invention relates also to a gene set (representing TOP2A index) consisting of TOP2A (Gene ID: 7153) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or all the genes mentioned in Table 1.
- the present invention further relates to a gene set (representing TOP2A index) consisting of RARA (Gene ID: 5914) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all the genes of Table 1.
- the present invention also relates to a gene set (representing TOP2A index) consisting of THRA (Gene ID: 7067) and further comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all the genes of Table 1.
- the present invention also relates to a gene set (representing TOP2A index) consisting of CDC6 (Gene ID: 990) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all the genes of Table 1.
- the present invention also relates to a gene set (representing TOP2A index) consisting of GSDMl (Gene ID: 284110) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
- the present invention also relates to a gene set (representing TOP2A index) consisting of PSMD3 (Gene ID: 5709) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
- the present invention also relates to a gene set (representing TOP2A index) consisting of CSF3 (Gene ID: 1440) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all the genes of Table 1.
- the present invention also relates to a gene set (representing TOP2A index) consisting of MED24 (Gene ID: 9862) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all the genes of Table 1.
- the present invention also relates to a gene set (representing TOP2A index) consisting of SNORD124 (Gene ID: 100113390) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
- the present invention also relates to a gene set (representing TOP2A index) consisting of NRlDl (Gene ID: 9572) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all the genes of Table 1.
- the present invention also relates to a gene set (representing TOP2A index) consisting of TRNASTOP-UCA (Gene ID: 100126534) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all the genes of Table 1.
- the present invention also relates to a gene set (representing TOP2A index) consisting of MSL-I (Gene ID: 339287) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
- the present invention also relates to a gene set (representing TOP2A index) consisting of CASC3 (Gene ID: 22794) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all the genes of Table 1.
- the present invention also relates to a gene set (representing TOP2A index) consisting of RAPGEFLl (Gene ID: 51195) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all the genes of Table 1.
- the present invention also relates to a gene set (representing TOP2A index) consisting of WIPF2 (Gene
- the present invention also relates to a gene set (representing TOP2A index) consisting of LOC100131821
- the present invention also relates to a gene set (representing TOP2A index) consisting of GJD3 (Gene ID:
- the present invention also relates to a gene set (representing TOP2A index) consisting of LOC390791 (Gene ID: 390791) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
- the present invention also relates to a gene set (representing TOP2A index) consisting of LOC728207 (Gene ID: 728207) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all the genes of Table 1.
- the present invention also relates to a gene set (representing TOP2A index) consisting of IGFBP4 (Gene ID: 3487) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all the genes of Table 1.
- the present invention also relates to a gene set (representing TOP2A index) consisting of TNS4 (Gene ID: 84951) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
- the present invention also relates to a gene set (representing TOP2A index) consisting of CCR7 (Gene ID: 1236) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
- the present invention also relates to a gene set (representing TOP2A index) consisting of SMARCEl (Gene ID: 6605) and of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or all the genes of Table 1.
- the present invention relates to a gene set (representing TOP2A index) comprising (or consisting of) two or three genes selected from the group consisting of CDC6 (Gene ID: 990), THRA (Gene ID: 9572), RARA (Gene ID: 5914) and TOP2A (Gene ID: 7153) .
- the present invention relates to a gene set (representing TOP2A index) comprising (or consisting of) two or three genes selected from the group consisting of CDC6 (Gene ID: 990), THRA (Gene ID: 9572), RARA (Gene ID: 5914) and TOP2A (Gene ID: 7153) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or all the genes of Table 1.
- the present invention relates to a gene set (representing TOP2A index) comprising (or consisting of) CDC6 (Gene ID: 990), RARA (Gene ID: 5914) and WIPF2 (Gene ID: 147179) .
- the present invention relates to a gene set (representing TOP2A index) comprising (or consisting of) THRA (Gene ID: 9572), CDC6 (Gene ID: 990), RARA (Gene ID: 5914) and TOP2A (Gene ID: 7153) .
- the present invention relates to a gene set (representing TOP2A index) comprising (or consisting of) THRA (Gene ID: 9572), CDC6 (Gene ID: 990), RARA (Gene ID: 5914) and TOP2A (Gene ID: 7153) and further comprising (consisting of) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or all the genes of Table 1.
- the present invention relates to a gene set (representing TOP2A index) that may further comprise 1, 2,
- the present invention relates to a gene set comprising (or consisting of) 1, 2, 3, 4, 5,
- the present invention relates to a gene set comprising (or consisting of) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65,
- the present invention relates to a gene set
- TOP2A index that further comprises 1, 2, 3,
- the present invention relates to a gene set (representing TOP2A index) that further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or all the genes of Table 11. [0053] The present invention relates to a gene set (representing TOP2A index) that further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or all the genes of Table 12.
- the present invention relates to a gene set (representing TOP2A index) that further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or all the genes of Table 13. [0055] The present invention relates to a gene set (representing TOP2A index) that further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or all the genes of Table 14. [0056] The present invention relates to a gene set (representing TOP2A index) that further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or all the genes of Table 15. [0057] The present invention relates to a gene set (representing TOP2A index) that further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or all the genes of Table 16.
- the present invention relates to a gene set (representing TOP2A index, the said genes representing Top2A index preferably (consisting of or) comprising CDC6, RARA and WIPF2) that further comprises FAM64A, KIF4A, NCAPH and STIL.
- the gene set (representing TOP2A index) comprises (or consists of) CDC6, RARA, WIPF2,
- FAM64A, KIF4A, NCAPH and STIL and further comprises 1, 2,
- the present invention relates to a gene set (representing TOP2A index) that further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or all the genes of Table 17.
- the present invention relates to a gene set (representing TOP2A index) that further comprises 1, 2, 3,
- the present invention further relates to a diagnostic kit or device comprising capture probes
- nucleotides sequences or proteinic probes such as antibodies, nanobodies or hypervariable portions thereof
- a solid support such as a multiwell plate or glass side
- target genes being complementary by hybridization to the capture probes
- their corresponding proteins encoded by these genes of the set of the invention (representing TOP2A index)
- the gene set of Tables 5 and/or 6 and possibly other means used for real time PCR analysis possibly fixed upon a solid support, (such as a multiwell plate or glass side) able to detect specifically, the expression of (complementary) target genes (being complementary by hybridization to the capture probes) (or their corresponding proteins encoded by these genes) of the set of the invention (representing TOP2A index) , and/or the gene set of Tables 5 and/or 6 and possibly other means used for real time PCR analysis.
- the kit or device according to the invention comprises means for real time PCR, preferably means for qRT-PCR.
- the kit or device of the invention is a computerized system comprising a bio-assay module configured for detecting a gene expression from a tumor sample (preferably a breast tumor sample) based upon the gene set or kit according of the invention and
- a processor module configured to calculate expression of these genes or protein synthesis of these genes and to generate a risk assessment for the tumor (preferably a breast tumor) sample.
- Another aspect of the invention concerns a method for a prediction (prognosis or prognostic) of cancer in mammal subject, which comprises the step of measuring gene expression in a (breast) tumor sample obtained from the said mammal subject, by putting into contact nucleotide sequences (or proteins) obtained from this tumor sample with the gene set, the kit or the device according to the invention and possibly generating a risk assessment for the said tumor sample by designating the outcome of a regimen comprising administration to the said mammal subject, of a sufficient amount of one or more Anthracycline compound (s) and by selecting the adequate compound to be administrated to this patient, preferably the sufficient amount of one or more anthracycline compound (s) .
- the patient is a human patient, suffering from a cancer selected from the group consisting of ovary cancer, breast cancer, lung cancer, cancer of the womb, cancer of the bladder, cancer of the stomach, sarcomas, thyroid cancer, leukaemia, Hodgkin's lymphoma and multiple myeloma (preferably a breast cancer, more preferably a ER- breast cancer still more preferably a ER- Her2+ breast cancer) .
- a cancer selected from the group consisting of ovary cancer, breast cancer, lung cancer, cancer of the womb, cancer of the bladder, cancer of the stomach, sarcomas, thyroid cancer, leukaemia, Hodgkin's lymphoma and multiple myeloma (preferably a breast cancer, more preferably a ER- breast cancer still more preferably a ER- Her2+ breast cancer) .
- the gene set, kit and device of the invention predicts the response of regimen consisting essentially into the administration to the tested patient of one or more Anthracycline compound (s), possibly combined with a simultaneous or a separated administration of another anti-tumoral therapeutic treatment or compound.
- Another aspect of the invention is related to an Anthracycline compound or a mixture of Anthracycline compounds (regimen) for use in the treatment (and/or the prevention) of cancer patients determined (as measured) by the gene set, kit or method of the invention.
- Anthracycline compound or a mixture of Anthracycline compounds is for use in the treatment (and/or prevention) of a cancer selected from the group consisting of ovary cancer, breast cancer, lung cancer, cancer of the womb, cancer of the bladder, cancer of the stomach, sarcomas, thyroid cancer, leukemias, Hodgkin's lymphoma and multiple myeloma, having (increased) index (as measured) according to Table 5 and/or a worse prediction (prognosis) assessed by the (prediction or prognostic) method of the invention.
- a cancer selected from the group consisting of ovary cancer, breast cancer, lung cancer, cancer of the womb, cancer of the bladder, cancer of the stomach, sarcomas, thyroid cancer, leukemias, Hodgkin's lymphoma and multiple myeloma, having (increased) index (as measured) according to Table 5 and/or a worse prediction (prognosis) assessed
- Anthracycline compound or a mixture of Anthracycline compounds is for use in the treatment (and/or prevention) of a cancer selected from the group consisting of ovary cancer, breast cancer, lung cancer, cancer of the womb, cancer of the bladder, cancer of the stomach, sarcomas, thyroid cancer, leukemias, Hodgkin's lymphoma and multiple myeloma, having (increased) index (as measured) according to Table 6 and/or a worse prediction (prognosis) assessed by the prediction (prognostic) method of the invention.
- a cancer selected from the group consisting of ovary cancer, breast cancer, lung cancer, cancer of the womb, cancer of the bladder, cancer of the stomach, sarcomas, thyroid cancer, leukemias, Hodgkin's lymphoma and multiple myeloma, having (increased) index (as measured) according to Table 6 and/or a worse prediction (prognosis) assessed by the
- Anthracycline compound or a mixture of Anthracycline compounds (regimen) is for use in the treatment (and/or prevention) of (breast) cancer, preferably ER- breast cancer, more preferably a ER- Her2- breast cancer having (increased) index (as measured) according to the prediction (prognostic) method of the invention .
- Anthracycline compound or a mixture of Anthracycline compounds is for use in the treatment (and/or prevention) of (an ER- Her2+ breast) cancer having (increased) index (as measured) according to the prediction (prognostic) method of the invention.
- Another aspect of the invention is related to a chemotherapeutic (anthracycline) compound (or regimen) for use in the treatment (and/or the prevention) of breast cancer having a specific (increased) index (as measured) according to Table 10 and/or Table 11, possibly combined with a specific (increased) TOP2A index (as measured according to Table 1), being preferably THRA (Gene ID: 9572), CDC6 (Gene ID: 990), RARA (Gene ID: 5914) and TOP2A (Gene ID: 7153) .
- Another aspect of the invention is related to a chemotherapeutic (anthracycline) compound (or regimen) for use in the treatment (and/or the prevention) of breast cancer having a specific index (as measured) according to Table 12 and/or Table 13 and/or Table 16, possibly combined with a specific (increased) TOP2A index (as measured according to Table 1), being preferably THRA (Gene ID: 9572), CDC6 (Gene ID: 990), RARA (Gene ID: 5914) and TOP2A (Gene ID: 7153) .
- a related aspect of the invention is a chemotherapeutic (anthracycline) compound (or regimen) for use in the treatment (and/or the prevention) of breast cancer having a specific (increased) index (as measured) according to Table 10 and/or Table 11, possibly combined with a specific (increased) index (as measured) according to Table 16, possibly combined with a specific (reduced) index (as measured) according to Table 12 and/or Table 13 possibly combined with a specific (increased) TOP2A index (as measured according to Table 1), being preferably THRA (Gene ID: 9572), CDC6 (Gene ID: 990), RARA (Gene ID: 5914) and TOP2A (Gene ID: 7153) or alternatively being CDC6, RARA and WIPF2.
- a last aspect of the invention is a method of treatment of patients comprising the steps of
- RARA stands for retinoic acid receptor, alpha; CDC6 for cell division cycle 6 homolog (S. cerevisiae) ; THRA for thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-erb-a) oncogene homolog, avian); GSDMl for gasdermin 1; PSMD3 for proteasome (prosome, macropain) 26S subunit, non-ATPase, 3; CSF3 for colony stimulating factor 3 (granulocyte); MED24 for mediator complex subunit 24; SNORD124 for small nucleolar RNA, C/D box 124; NRlDl for nuclear receptor subfamily 1, group D, member 1; TRNASTOP- UCA for transfer RNA opal suppressor (anticodon UCA) ; MSL-I for male-specific lethal-1 homolog; CASC3 for cancer susceptibility candidate 3; RAPGEFLl for Rap guanine nucleotide exchange factor (GEF) -like 1; WIPF2 for
- a pathological complete response (pCR) rate of 15% was obtained, 14% and 16% for patients treated with the 3-weekly and dose-dense scheme respectively.
- the patient and tumour baseline characteristics are illustrated in Table 2.
- Ki67 protein expression (a proliferation marker) was not significantly associated w i th pCR , bo th when considering it as a continuous and binary variable (Table 3) .
- TOP2A was represented by 3 different Affymetrix probe-sets: 201 291_s_at, 201 292_at and 237 469_at. Since the probe-set 201 291_s_at showed the greatest variance, the inventors used that probe-set for further analyses.
- FISH results were available for 113 out of the 149 patients. Out of these samples, 36 were HER2 amplified (32%); TOP2A was amplified in 12 patients (11% of the global population) and deleted in 16 patients (14% of the population) .
- TOP2A measures by IHC were available for 120 patients. The median percentage of positively stained cells was 15% (range 0-90%) .
- TOP2A expression was considered as a continuous variable, the inventors did not observe any correlation with FISH results (based on the 99 ER-negative samples available for this comparison) .
- Table 4 TOP2A gene, mRNA and protein levels with regard to the clinic-pathologic parameters
- T0P2 mRNA levels (considered as a continuous variable or as a binary variable with the median as cut point) and TOP2A protein levels were not associated with response to therapy.
- FEC anthracyclines-based regimen
- TET taxane-based regimen
- TOP2A gene index predicts a better response to anthracyclines in the whole ER- patients and especially in ER-/HER2+ patients) .
- TOP2A index clearly outperformed mRNA measurements of TOP2A amplification. ( Figure 3) .
- the inventors further investigated the predictive value of the gene expression modules that they developed previously in WO 2009/030770 and Desmedt et al . Clin Can Res 2008) .
- high levels of the estrogen receptor module were statistically associated with response to anthracyclines, whereas high levels of the tumor invasion module were associated with the presence of residual disease.
- PLAU which is the prototype from the tumor invasion gene expression module of WO 2009/030770 and of Table 13 of the present invention
- EGFR whose over- expression has been correlated with poor survival (Bartlett et al . 2008) and with resistance to anthracyclines-based chemotherapy in triple-negative breast cancer
- TP53 whose predictive value for efficacy of anthracyclines-based chemotherapy has been matter of controversy and many others .
- the IAP analysis which included 218 genes, revealed that cellular movement, cellular growth and proliferation, cell-to-cell signaling, cell death and cellular assembly were the most significant functional classes.
- AI225238 1 Hs.445500 NM_00595 MT1X -1 Hs.374950 BG540628 IGKV 1-5 1
- NM_030754 SAA1 /// S -1 Hs.332053 AU 159942 TOP2A 1 Hs.156346 BE465475 KBTB D9 -1 Hs.130593
- Table 8 Results of the predictive ability of the de-novo gene signatures, presented as C-indices, in the validation cohort, according to treatment arm and HER2 mRNA status
- the inventors then combined the present invention with the results they previously obtained (Desmedt et al . , 2008) .
- the inventors coupled the gene set of the invention, with a gene set comprising several genes from Table 10 (immune module 1) . gene.symbol EntrezGene.ID gene.symbol EntrezGene.ID gene.symbol EntrezGene.ID
- the inventors measured that increased expression of TOP2A index coupled with increased expression of genes of Table 10 increased the prognosis for chemotherapy (anthracyclines) and/or positively correlate with the response to chemotherapy (anthracyclines) .
- the inventors coupled the gene set of the invention, with a gene set comprising several genes from Table 11 (immune module 2) . gene.symbol EntrezGene.ID gene.symbol EntrezGene.ID gene.symbol EntrezGene.ID
- the inventors measured that increased expression of TOP2A index coupled with increased expression of genes of Table 11 increased the prognosis for chemotherapy (anthracyclines) and/or positively correlate with the response to chemotherapy (anthracyclines) .
- the inventors coupled the gene set of the invention, with a gene set comprising several genes from Table 12 (stroma module 1) . gene.symbol EntrezGene.ID gene.symbol EntrezGene.ID gene.symbol EntrezGene.ID gene.symbol EntrezGene.ID
- the inventors measured that increased expression of TOP2A index coupled with reduced expression of genes of Table 12 increased the prognosis for chemotherapy (anthracyclines) and/or negatively correlate with the response to chemotherapy (anthracyclines) .
- the inventors coupled the gene set of the invention, with a gene set comprising several genes from Table 13 : stroma module 2 gene.symbol EntrezGene.ID gene.symbol EntrezGene.ID gene.symbol EntrezGene.ID gene.symbol EntrezGene.ID
- the inventors coupled the gene set of the invention, with a gene set comprising several genes from Table 14 (ESR-) .
- ESR- The inventors measured that increased expression of TOP2A index coupled with increased expression of genes of Table 14 increased the prognosis for chemotherapy (anthracyclines) and/or positively correlate with the response to chemotherapy (anthracyclines) .
- the inventors coupled the gene set of the invention, with a gene set comprising several genes from Table 15 and measured that increased expression of TOP2A index coupled with increased expression of genes of Table 15 increased the prognosis for chemotherapy (anthracyclines) and/or positively correlate with the response to chemotherapy (anthracyclines) .
- the inventors coupled the gene set of the invention, with a gene set comprising several genes from Table 16.
- Table 16 AURKA proliferation module
- the inventors coupled the gene set of the invention, with a gene set comprising several genes from Table 17 (VEGF) .
- VEGF Table 17
- the inventors coupled the gene set of the invention, with a gene set comprising several genes from Table 18 (CASP3) .
- Anthracyclines (Epirubicin) monotherapy (100 mg/m2) was given as neo-adjuvant chemotherapy: every 3 weeks x 4 cycles for early BC or every 2 weeks x 6 cycles with Neulasta® 6mg on day 2 for patients with inflammatory or locally advanced breast cancer.
- every patient underwent surgery with axillary node sampling.
- adjuvant docetaxel 100 mg/m2 x 4 cycles
- loco-regional irradiation were administered using standard criteria. This study was primarily designed for the identification of biomarkers of response to anthracyclines (epirubicin) .
- This validation cohort includes patients reported by Bonnefoi et al . These patients are a subgroup of the patients included in the prospective phase III intergroup trial of neoadjuvant chemotherapy (European Orga.nisa.tion for Research and Treatment of Cancer [EORTC] 10994/Breast International Group [BIGj 00-01, registered as NCT00017095) .
- Microarray data were deposited in the Gene Expression Omnibus database under accession number GSE6861.
- FISH assays were done with the Abbott Multicolor TOP2A Spectrum orange, HER2 Spectrum green and CEP17 Spectrum aqua probe. Briefly, the sections were deparaffined and incubated in pre-treatment buffer at 80 0 C for 30 min. Enzymatic digestion was carried out with pepsin (10-20 min at 37°C) and the slides were dehydrated in graded dilutions of ethanol . The probe (10 ⁇ l) was applied to the slides under coverslips. The slides were co- denatured on a hot plate (73°C for 5 min), followed by overnight hybridization at 37°C.
- the slides were counterstained with 10 ⁇ l of 0.2 ⁇ M 4 , 6-diamino-2- phenylindole (DAPI) in antifade solution (Vectashield, Vector Laboratories, Inc., Burlingame, CA) .
- FISH was evaluated using an Olympus BX51 epifluorescence microscope. The invasive part of the tumor was circled on the slides with a diamond by superposition with haematoxylin-stained sections previously analyzed by the pathologist (DL) . Signals from at least 60 non-overlapping nuclei with intact morphology were evaluated to determine the mean number of signals/cell (ratio between mean number of TOP2A or HER2 signals and the mean
- IHC Immunohistochemistry
- Ki-67 evaluation was carried out routinely by IHC using the monoclonal mouse antibody MIB-I (1/50, Dako, Carpinteria, CA) .
- MIB-I monoclonal mouse antibody
- the sections were dewaxed and rehydrated.
- a microwave (two times 10 min at 650 W) antigen retrieval method in citrate buffer pH 6.0 was implemented before using the Ventana Nexes automated immunostainer with standard Nexes reagents (Ventana Medical Systems, Arlington, AZ) .
- a cutoff of 25% of positively stained cells was used (Durbecq et al . 2004) .
- RNA amplification, hybridization and image scanning were done according to standard Affymetrix protocols. The inventors have used the Affymetrix Human Genome U133-2.0 plus GeneChip .
- index is the expression of a gene included in the index and w ⁇ is its coefficient.
- This index is a combination of table 1 genes.
- the inventors used an index made of the preferred genes :TOP2A, THRA, CDC6 and RARA.
- TOP2A 201 291_s_at
- AUC area under the curve
- the inventors computed the prognostic value of a signature score through a meta-analytical framework.
- the corresponding gene module scores were computed in order to identify the breast cancer molecular subtype in this two dimensional space using a mixture of three Gaussians.
- the three subtypes are denoted by ER-/HER- (basal), HER2+ (ERBB2-enriched) and ER+/HER2- (luminal) .
- Functional analysis of the gene signatures was performed using Ingenuity Pathways Analysis (IPA) tools version 3.0. Affymetrix probe sets of each cluster were used as input and IPA then calculated a significance value for enrichment of the functional classes. Only significant functions are shown.
- IPA Ingenuity Pathways Analysis
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2010238486A AU2010238486A1 (en) | 2009-04-17 | 2010-04-16 | Methods and tools for predicting the efficiency of anthracyclines in cancer |
US13/264,726 US20120065084A1 (en) | 2009-04-17 | 2010-04-16 | Methods and tools for predicting the efficiency of anthracyclines in cancer |
CA2758277A CA2758277A1 (en) | 2009-04-17 | 2010-04-16 | Methods and tools for predicting the efficiency of anthracyclines in cancer |
EP20100715211 EP2419532A1 (en) | 2009-04-17 | 2010-04-16 | Methods and tools for predicting the efficiency of anthracyclines in cancer |
JP2012505181A JP2012523828A (en) | 2009-04-17 | 2010-04-16 | Methods and tools for predicting the efficacy of anthracyclines in cancer |
IL215372A IL215372A0 (en) | 2009-04-17 | 2011-09-25 | Methods and tools for predicting the efficiency of anthracyclines in cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP2009/054606 | 2009-04-17 | ||
PCT/EP2009/054606 WO2010118782A1 (en) | 2009-04-17 | 2009-04-17 | Methods and tools for predicting the efficiency of anthracyclines in cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010119133A1 true WO2010119133A1 (en) | 2010-10-21 |
Family
ID=41382440
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/054606 WO2010118782A1 (en) | 2009-04-17 | 2009-04-17 | Methods and tools for predicting the efficiency of anthracyclines in cancer |
PCT/EP2010/055067 WO2010119133A1 (en) | 2009-04-17 | 2010-04-16 | Methods and tools for predicting the efficiency of anthracyclines in cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/054606 WO2010118782A1 (en) | 2009-04-17 | 2009-04-17 | Methods and tools for predicting the efficiency of anthracyclines in cancer |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP2012523828A (en) |
AU (1) | AU2010238486A1 (en) |
CA (1) | CA2758277A1 (en) |
IL (1) | IL215372A0 (en) |
WO (2) | WO2010118782A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011302004B2 (en) * | 2010-09-15 | 2015-10-29 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201018312D0 (en) * | 2010-10-29 | 2010-12-15 | Vib Vzw | Metagene expression signature for prognosis of breast cancer patients |
GB201306147D0 (en) * | 2013-04-05 | 2013-05-22 | Univ Ha Il | Novel biomarker signature and uses thereof |
EP3140420B1 (en) | 2014-05-07 | 2019-09-11 | Universite Libre De Bruxelles | Breast cancer epigenetic markers useful in anthracycline treatment prognosis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050064455A1 (en) * | 2003-05-28 | 2005-03-24 | Baker Joffre B. | Gene expression markers for predicting response to chemotherapy |
WO2007070640A2 (en) * | 2005-12-14 | 2007-06-21 | Wigler Michael H | Use of roma for characterizing genomic rearrangements |
WO2009030770A2 (en) | 2007-09-07 | 2009-03-12 | Universite Libre De Bruxelles | Methods and tools for prognosis of cancer in er- patients |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2465916A1 (en) * | 2001-11-09 | 2003-05-15 | The University Of Manitoba | Treatment of breast cancer |
EP1365034A3 (en) * | 2002-05-21 | 2004-02-18 | Bayer HealthCare AG | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia |
JPWO2005007846A1 (en) * | 2003-04-25 | 2006-08-31 | 財団法人癌研究会 | Method for determining the sensitivity of tumor cells to anticancer agents |
EP1644732B1 (en) * | 2003-07-10 | 2010-02-24 | Central Institute For Experimental Animals | Animal model for the analysis of tumor metastasis |
EP1961827A3 (en) * | 2004-07-18 | 2008-09-17 | Epigenomics AG | Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders |
CA2575557A1 (en) * | 2004-07-30 | 2006-02-09 | Rosetta Inpharmatics Llc | Prognosis of breast cancer patients |
WO2006084272A2 (en) * | 2005-02-04 | 2006-08-10 | Rosetta Inpharmatics Llc | Methods of predicting chemotherapy responsiveness in breast cancer patients |
JP2005323600A (en) * | 2005-06-06 | 2005-11-24 | National Institute Of Advanced Industrial & Technology | Method for evaluating estrogen activity-suppressing effect using gene expression as index |
US8700335B2 (en) * | 2006-05-18 | 2014-04-15 | Caris Mpi, Inc. | System and method for determining individualized medical intervention for a disease state |
US20090280493A1 (en) * | 2006-09-08 | 2009-11-12 | Siemens Healthcare Diagnostics Inc. | Methods and Compositions for the Prediction of Response to Trastuzumab Containing Chemotherapy Regimen in Malignant Neoplasia |
EP1961825A1 (en) * | 2007-02-26 | 2008-08-27 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting the occurrence of metastasis in breast cancer patients |
AU2008264893A1 (en) * | 2007-04-16 | 2008-12-24 | Inserm- Institut National De La Sante Et De La Recherche Medicale | Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer |
EP2191020A2 (en) * | 2007-08-16 | 2010-06-02 | Genomic Health, Inc. | Gene expression markers of recurrence risk in cancer patients after chemotherapy |
-
2009
- 2009-04-17 WO PCT/EP2009/054606 patent/WO2010118782A1/en active Application Filing
-
2010
- 2010-04-16 JP JP2012505181A patent/JP2012523828A/en active Pending
- 2010-04-16 WO PCT/EP2010/055067 patent/WO2010119133A1/en active Application Filing
- 2010-04-16 CA CA2758277A patent/CA2758277A1/en not_active Abandoned
- 2010-04-16 AU AU2010238486A patent/AU2010238486A1/en not_active Abandoned
-
2011
- 2011-09-25 IL IL215372A patent/IL215372A0/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050064455A1 (en) * | 2003-05-28 | 2005-03-24 | Baker Joffre B. | Gene expression markers for predicting response to chemotherapy |
WO2007070640A2 (en) * | 2005-12-14 | 2007-06-21 | Wigler Michael H | Use of roma for characterizing genomic rearrangements |
WO2009030770A2 (en) | 2007-09-07 | 2009-03-12 | Universite Libre De Bruxelles | Methods and tools for prognosis of cancer in er- patients |
Non-Patent Citations (16)
Title |
---|
ARRIOLA EDURNE ET AL: "Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.", BREAST CANCER RESEARCH AND TREATMENT DEC 2007 LNKD- PUBMED:17260090, vol. 106, no. 2, December 2007 (2007-12-01), pages 181 - 189, XP002585434, ISSN: 0167-6806 * |
BARTLETT ET AL., J. CLIN. ONCOL, vol. 31, 2008, pages 5027 - 5035 |
BONNEFOI ET AL., LANCET ONCOLOGY, vol. 8, 2007, pages 1071 - 1078 |
CALLAGY GRACE ET AL: "Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays", JOURNAL OF PATHOLOGY, JOHN WILEY & SONS LTD, GB LNKD- DOI:10.1002/PATH.1694, vol. 205, no. 3, 1 February 2005 (2005-02-01), pages 388 - 396, XP002444116, ISSN: 0022-3417 * |
DESMEDT ET AL., CLIN CAN RES, 2008 |
DI LEO A ET AL., CANCER RES., vol. 69, 2009, pages 705 |
DI LEO ANGELO ET AL: "Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?", EUROPEAN JOURNAL OF CANCER (OXFORD, ENGLAND : 1990) DEC 2008 LNKD- PUBMED:18993056, vol. 44, no. 18, December 2008 (2008-12-01), pages 2791 - 2798, XP002585439, ISSN: 1879-0852 * |
DI LEO ET AL., EUR. J. OF CANCER, vol. 44, 2008, pages 2791 - 2798 |
JORGENSEN J T ET AL: "Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer", THE ONCOLOGIST, ALPHAMED PRESS, US LNKD- DOI:10.1634/THEONCOLOGIST.12-4-397, vol. 12, no. 4, 1 April 2007 (2007-04-01), pages 397 - 405, XP002444118, ISSN: 1083-7159 * |
KNOOP ET AL., J. CLIN ONCOL, vol. 23, 2005, pages 7483 - 7490 |
MANO M S ET AL: "Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.", GYNECOLOGIC ONCOLOGY MAR 2004 LNKD- PUBMED:14984957, vol. 92, no. 3, March 2004 (2004-03-01), pages 887 - 895, XP002585438, ISSN: 0090-8258 * |
PAWITAN YUDI ET AL: "Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.", BREAST CANCER RESEARCH : BCR 2005 LNKD- PUBMED:16280042, vol. 7, no. 6, 2005, pages R953 - R964, XP002585435, ISSN: 1465-542X * |
PETIT ET AL., EUR J CANCER, vol. 40, 2004, pages 205 - 11 |
RODY A ET AL: "Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.", BREAST CANCER RESEARCH AND TREATMENT FEB 2009 LNKD- PUBMED:18340528, vol. 113, no. 3, February 2009 (2009-02-01), pages 457 - 466, XP002585436, ISSN: 1573-7217 * |
SCHINDLBECK C ET AL: "Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY AUG 2005 LNKD- PUBMED:15887027, vol. 131, no. 8, August 2005 (2005-08-01), pages 539 - 546, XP002585437, ISSN: 0171-5216 * |
TANNER M ET AL: "Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401", 1 June 2006, JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US LNKD- DOI:10.1200/JCO.2005.02.9264, PAGE(S) 2428 - 2436, ISSN: 0732-183X, XP002444117 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011302004B2 (en) * | 2010-09-15 | 2015-10-29 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
Also Published As
Publication number | Publication date |
---|---|
AU2010238486A1 (en) | 2011-11-03 |
JP2012523828A (en) | 2012-10-11 |
IL215372A0 (en) | 2011-12-29 |
CA2758277A1 (en) | 2010-10-21 |
WO2010118782A1 (en) | 2010-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220396842A1 (en) | Method for using gene expression to determine prognosis of prostate cancer | |
US20170107577A1 (en) | Determining Cancer Aggressiveness, Prognosis and Responsiveness to Treatment | |
US20210062275A1 (en) | Methods to predict clinical outcome of cancer | |
ES2525382T3 (en) | Method for predicting breast cancer recurrence under endocrine treatment | |
AU2010326066A1 (en) | Classification of cancers | |
US20100292933A1 (en) | Methods, systems, and compositions for classification, prognosis, and diagnosis of cancers | |
JP2014509189A (en) | Colon cancer gene expression signature and methods of use | |
US20100298160A1 (en) | Method and tools for prognosis of cancer in er-patients | |
US20190367964A1 (en) | Dissociation of human tumor to single cell suspension followed by biological analysis | |
AU2020201779A1 (en) | Method for using gene expression to determine prognosis of prostate cancer | |
US20110306507A1 (en) | Method and tools for prognosis of cancer in her2+partients | |
EP2419532A1 (en) | Methods and tools for predicting the efficiency of anthracyclines in cancer | |
WO2010119133A1 (en) | Methods and tools for predicting the efficiency of anthracyclines in cancer | |
US20100055686A1 (en) | Methods for diagnosis of pediatric common acute lymphoblastic leukemia by determining the level of gene expression | |
WO2017178612A1 (en) | Method of stratification of patients suffering from cancer | |
엄혜현 | Analysis of genetic heterogeneity of tumor-infiltrating immune cells in human cancer by single-cell RNA sequencing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10715211 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2758277 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012505181 Country of ref document: JP Ref document number: 2010715211 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13264726 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2010238486 Country of ref document: AU Date of ref document: 20100416 Kind code of ref document: A |